JP2020535193A - 結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス - Google Patents

結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス Download PDF

Info

Publication number
JP2020535193A
JP2020535193A JP2020517938A JP2020517938A JP2020535193A JP 2020535193 A JP2020535193 A JP 2020535193A JP 2020517938 A JP2020517938 A JP 2020517938A JP 2020517938 A JP2020517938 A JP 2020517938A JP 2020535193 A JP2020535193 A JP 2020535193A
Authority
JP
Japan
Prior art keywords
formula
linagliptin
reaction mass
linagliptin intermediate
intermediate represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020517938A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535193A5 (enExample
Inventor
パレ，ヴェンカタ，ラガヴェンドラチャリュル
ラジマヘンドラ，シャンムガサミー
チャンドレゴウダ，ダルシャン，ジャッカリ
ポンヌサミー，タンガラス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocon Ltd
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of JP2020535193A publication Critical patent/JP2020535193A/ja
Publication of JP2020535193A5 publication Critical patent/JP2020535193A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020517938A 2017-09-27 2018-09-27 結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス Pending JP2020535193A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201741034292 2017-09-27
IN201741034292 2017-09-27
PCT/IB2018/057484 WO2019064214A1 (en) 2017-09-27 2018-09-27 INTERMEDIATE OF CRYSTALLINE LINAGLIPTIN AND PROCESS FOR THE PREPARATION OF LINAGLIPTIN

Publications (2)

Publication Number Publication Date
JP2020535193A true JP2020535193A (ja) 2020-12-03
JP2020535193A5 JP2020535193A5 (enExample) 2021-10-28

Family

ID=65903063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020517938A Pending JP2020535193A (ja) 2017-09-27 2018-09-27 結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス

Country Status (10)

Country Link
US (1) US11040974B2 (enExample)
JP (1) JP2020535193A (enExample)
KR (1) KR20200092946A (enExample)
CN (1) CN111511743A (enExample)
AU (1) AU2018343236A1 (enExample)
BR (1) BR112020005964A2 (enExample)
CA (1) CA3076980A1 (enExample)
MX (1) MX2020004050A (enExample)
RU (1) RU2020114890A (enExample)
WO (1) WO2019064214A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110684026A (zh) * 2019-10-24 2020-01-14 扬子江药业集团上海海尼药业有限公司 一种利格列汀的工业化制备方法
CN110872292B (zh) * 2019-11-30 2022-01-25 江苏君若药业有限公司 一条合成糖尿病药物利拉利汀的路线
EP4349837A1 (en) 2022-10-05 2024-04-10 Zaklady Farmaceutyczne "Polpharma" S.A. A pharmaceutical intermediate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015011609A1 (en) * 2013-07-23 2015-01-29 Ranbaxy Laboratories Limited Process for the preparation of linagliptin and an intermediate thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
IN2013MU02055A (enExample) * 2013-06-18 2015-07-03 Cadila Healthcare Ltd

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015011609A1 (en) * 2013-07-23 2015-01-29 Ranbaxy Laboratories Limited Process for the preparation of linagliptin and an intermediate thereof

Also Published As

Publication number Publication date
CA3076980A1 (en) 2019-04-04
US11040974B2 (en) 2021-06-22
KR20200092946A (ko) 2020-08-04
AU2018343236A1 (en) 2020-05-14
MX2020004050A (es) 2020-11-06
RU2020114890A (ru) 2021-10-27
US20200354363A1 (en) 2020-11-12
WO2019064214A1 (en) 2019-04-04
BR112020005964A2 (pt) 2020-10-06
CN111511743A (zh) 2020-08-07

Similar Documents

Publication Publication Date Title
EP2970123B1 (en) Salt of omecamtiv mecarbil and process for preparing salt
TWI597280B (zh) 化合物之晶型、其製備及用途
EP2985277A1 (en) Dipyrromethene crystal and method for manufacturing same
EP3376870B1 (en) Process for the preparation of kinase inhibitors and intermediates thereof
JP2023017840A (ja) Ｍｋ２阻害剤の形態および組成物
JP2019518776A (ja) Ｅｇｆｒ阻害剤としてのアニリンピリミジン化合物の結晶
JP2022520629A (ja) 固体形態のｆｇｆｒ阻害剤化合物およびその製造方法
CZ2014502A3 (cs) Nová forma sofosbuviru a způsob její přípravy
US11040974B2 (en) Crystalline linagliptin intermediate and process for preparation of linagliptin
JP6632127B2 (ja) トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物およびその中間体の製造方法
US11827614B2 (en) Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates
US8278484B2 (en) Process for preparing a benzoylbenzeneacetamide derivative
US11203585B2 (en) Crystalline forms of lenalidomide
EP4582419A1 (en) Method for producing quinoxaline derivative
EP4644374A1 (en) Naphthylamide compound, and preparation method therefor and use thereof
HK1241358A1 (en) Crystal of (s)-1-(2-hydroxyethyl)-4-methyl-n- [4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]- 1h-pyrrole-3-carboxamide
HK1218544B (en) Salt of omecamtiv mecarbil and process for preparing salt

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230412